- Home
- SHO vs AKRO Comparison
SHO vs AKRO Comparison
Compare SHO & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHO
- AKRO
- Stock Information
- Founded
- SHO 1995
- AKRO 2017
- Country
- SHO United States
- AKRO United States
- Employees
- SHO 36
- AKRO N/A
- Industry
- SHO Hotels/Resorts
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- SHO Consumer Discretionary
- AKRO Health Care
- Exchange
- SHO Nasdaq
- AKRO Nasdaq
- Market Cap
- SHO 1.7B
- AKRO 3.9B
- IPO Year
- SHO 1995
- AKRO 2019
- Fundamental
- Price
- SHO $9.16
- AKRO $51.69
- Analyst Decision
- SHO Hold
- AKRO Strong Buy
- Analyst Count
- SHO 8
- AKRO 6
- Target Price
- SHO $9.56
- AKRO $82.50
- AVG Volume (30 Days)
- SHO 2.8M
- AKRO 1.6M
- Earning Date
- SHO 08-06-2025
- AKRO 08-08-2025
- Dividend Yield
- SHO 3.95%
- AKRO N/A
- EPS Growth
- SHO N/A
- AKRO N/A
- EPS
- SHO 0.10
- AKRO N/A
- Revenue
- SHO $922,708,000.00
- AKRO N/A
- Revenue This Year
- SHO $7.67
- AKRO N/A
- Revenue Next Year
- SHO $3.45
- AKRO N/A
- P/E Ratio
- SHO $92.87
- AKRO N/A
- Revenue Growth
- SHO N/A
- AKRO N/A
- 52 Week Low
- SHO $7.45
- AKRO $21.34
- 52 Week High
- SHO $12.41
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- SHO 59.10
- AKRO 45.35
- Support Level
- SHO $8.70
- AKRO $50.13
- Resistance Level
- SHO $9.30
- AKRO $53.60
- Average True Range (ATR)
- SHO 0.24
- AKRO 2.03
- MACD
- SHO 0.04
- AKRO -0.83
- Stochastic Oscillator
- SHO 83.57
- AKRO 6.37
About SHO Sunstone Hotel Investors Inc. Sunstone Hotel Investors Inc.
Sunstone Hotel Investors Inc is a real estate investment trust that acquires, owns, manages, and renovates the full-service hotel and select-service hotel properties across various states in the United States. Its firm's portfolio consists upper upscale and luxury hotels located in convention, resort destination and urban markets. Its majority of the hotels operate under a brand owned by Marriott, Hilton, Hyatt, Four Seasons or Montage. It operates geographically in Califiornia which generates the majority of its revenue; Florida; and Hawaii. The company's sole source of income is hotel revenue from its hotel ownership segment.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.